• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

iCAD plans to supply lung cancer software

Article

Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection,

Software developer iCAD and image processing specialist TeraRecon have signed a nonexclusive product licensing and distribution agreement under which TeraRecon will develop a new server-based product offering to include iCAD lung cancer detection, analysis, and tracking software. Product release is expected in 2005. The stand-alone server product will work in concert with existing PACS and DICOM review equipment, as well as other products in the TeraRecon Aquarius product line. The three-year agreement provides for worldwide distribution through TeraRecon's direct sales force, independent resellers/distributors, and OEM partnerships. The companies have agreed to work together to obtain the FDA approvals necessary for U.S. distribution.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.